

Table S4. Clinical and pathological characteristics of the 67 STS patients analyzed for circulating levels of periostin

Variable		Patients N (%)	Histotype		
			LMS	MFS	UPS
Age (years)	≤70	39 (58.2%)	21 (70.0%)	12 (52.2%)	6 (42.9%)
	>70	28 (41.8%)	9 (30.0%)	11 (47.8%)	8 (57.1%)
Gender	M	36 (53.7%)	14 (46.7%)	15 (65.2%)	7 (50.0%)
	F	31 (46.3%)	16 (53.3%)	8 (34.8%)	7 (50.0%)
Grade	G1+G2	23 (34.3%)	11 (36.7%)	11 (47.8%)	1 (7.1%)
	G3	44 (65.7%)	19 (63.3%)	12 (52.2%)	13 (92.9%)
Tumor size	≤5 cm	12 (17.9%)	9 (30.0%)	1 (4.4%)	2 (14.3%)
	>5 cm	55 (82.1%)	21 (70.0%)	22 (95.6%)	12 (85.7%)
Metastasis at diagnosis	Yes	7 (10.5%)	7 (23.3%)	0	0
	No	60 (89.5%)	23 (76.7%)	23	14
Survival status	Alive	30 (44.8%)	10 (33.3%)	16 (69.6%)	4 (28.6%)
	Dead	37 (55.2%)	20 (66.7%)	7 (30.4%)	10 (71.4%)
Histotype	LMS	30 (44.8%)			
	MFS	23 (34.3%)			
	UPS	14 (20.9%)			

Abbreviations: LMS, leiomyosarcoma; MFS, myxofibrosarcoma; UPS, undifferentiated pleomorphic sarcoma.